

Supplemental content for the article titled “Infantile Hemangiomas, Part 1: Treatment with Oral Propranolol Hydrochloride,” which was published in the September/October 2011 issue of the International Journal of Pharmaceutical Compounding. The following list provides the references for the published article.

References

- Kilcline C, Frieden IJ. Infantile hemangiomas: How common are they? A systematic review of the medical literature. *Pediatr Dermatol* 2008; 25(2): 168–173.
- Zimmermann A.P, Wiegand S, Werner JA. Propranolol therapy for infantile haemangiomas: Review of the literature. *Int J Pediatr Otorhinolaryngol* 2010; 74(4): 338–342.
- Léauté-Labrèze C, Taieb A. Efficacy of beta-blockers in infantile capillary haemangiomas: The physiopathological significance and therapeutic consequences. *Ann Dermatol Venereol* 2008; 135(12): 860–862.
- Drolet BA, Juern A. *Infantile Hemangiomas: Diagnosis and Treatment*. [Children’s Hospital of Wisconsin Website.] Available at: www.chw.org/display/PPF/DocID/43150/Nav/1/router.asp. Accessed January 2011.
- Eivazi B, Ardelean M, Bäumlner W et al. Update of hemangiomas and vascular malformations of the head and neck. *Eur Arch Otorhinolaryngol* 2009; 266(2):187–197.
- Werner JA, Dünne AA, Lippert BM et al. Optimal treatment of vascular birthmarks. *Am J Clin Dermatol* 2003; 4(11): 745–756.
- Boye E, Jinnin M, Olsen BR. Infantile hemangioma: challenges, new insights, and therapeutic promise. *J Craniofac Surg* 2009; 20(Suppl 1): 678–684.
- Chiller KG, Passaro D, Frieden IJ. Hemangiomas of infancy: Clinical characteristics, morphologic subtypes, and their relationship to race, ethnicity, and sex. *Arch Dermatol* 2002; 138(12): 1567–1576.
- Haggstrom AN, Lammer EJ, Schneider RA et al. Patterns of infantile hemangiomas: New clues to hemangioma pathogenesis and embryonic facial development. *Pediatrics* 2006; 117(3): 698–703.
- Waner M, North PE, Scherer KA et al. The nonrandom distribution of facial hemangiomas. *Arch Dermatol* 2003; 139(7): 869–875.
- Drolet BA, Chamlin SL, Garzon MC et al. Prospective study of spinal anomalies in children with infantile hemangiomas of the lumbosacral skin. *J Pediatr* 2010; 157(5): 789–794.
- Mulliken JB, Fishman SJ, Burrows PE. Vascular Anomalies. *Curr Probl Surg* 2000; 37: 517–584.
- Chang LC, Haggstrom AN, Drolet BA et al. Growth characteristics of infantile hemangiomas: Implications for management. *Pediatrics* 2008; 122(2): 360–367.
- Haggstrom AN, Drolet BA, Baselga E, et al. Prospective study of infantile hemangiomas: Clinical characteristics predicting complications and treatment. *Pediatrics* 2006; 118(3): 882–887.
- Mulliken JB. Update on hemangioma. *Int Pediatr* 1999; 14: 132–134.
- Huang SA, Tu HM, Harney JW et al. Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. *N Engl J Med* 2000; 343(3): 185–189.
- [No author listed.] Atlas of Dermatology. *Infantile Hemangiomas*. [Atlas of Dermatology Website.] Available at: www.dermaamin.com/site/atlas-of-dermatology/8-i/712-infantile-hemangioma-.html. Accessed January 2011.
- Perkins JA, Duke W, Chen E et al. Emerging concepts in airway infantile hemangioma assessment and management. *Otolaryngol Head Neck Surg* 2009; 141(2): 207–212.
- Perkins JA, Oliaei S, Garrison MM et al. Airway procedures and hemangiomas: Treatment patterns and outcome in U.S. pediatric hospitals. *Int J Pediatr Otorhinolaryngol* 2009; 73(9): 1302–1307.
- Buckmiller LM, Munson PD, Dyamenahalli U et al. Propranolol for infantile hemangiomas: Early experience at a tertiary vascular anomalies center. *Laryngoscope* 2010; 120(4): 676–681.
- Metry DW, Haggstrom AN, Drolet BA et al. A prospective study of PHACE syndrome in infantile hemangiomas: Demographic features, clinical findings, and complications. *Am J Med Genet A* 2006; 140(9): 975–986.
- Drolet BA, Swanson EA, Frieden IJ; Hemangioma Investigator Group. Infantile hemangiomas: An emerging health issue linked to an increased rate of low birth weight infants. *J Pediatr* 2008; 153(5): 712–715.
- Haggstrom AN, Drolet BA, Baselga E et al; Hemangioma Investigator Group. Prospective study of infantile hemangiomas: Demographic, prenatal, and perinatal characteristics. *J Pediatr* 2007; 150(3): 291–294.
- Jinnin M, Ishihara T, Boye E et al. Recent progress in studies of infantile hemangioma. *J Dermatol* 2010; 37(4): 283–298.
- Maguiness SM, Freiden I.J. Current management of infantile hemangiomas. *Semin Cutan Med Surg* 2010; 29(2): 106–114.
- Bennet ML, Fleischer AB Jr, Chamlin SL et al. Oral corticosteroid use is effective for cutaneous hemangiomas: An evidence-based evaluation. *Arch Dermatol* 2001; 137(9): 1208–1213.
- Bruckner AL, Frieden IJ. Hemangiomas of infancy. *J Am Acad Dermatol* 2003; 48(4): 477–493.
- Michaud AP, Baumann NM, Burke DK et al. Spastic diplegia and other motor disturbances in infants receiving interferon-alpha. *Laryngoscope* 2004; 114(7): 1231–1236.
- Léauté-Labrèze C, Dumas de la Roque E, Hubiche T et al. Propranolol for severe hemangiomas of infancy. *N Engl J Med* 2008; 358(24): 2649–2651.
- Denoyelle F, Garabédian EN. Propranolol may become first-line treatment in obstructive subglottic hemangiomas. *Otolaryngol Head Neck Surg* 2010; 142(3): 463–464.
- Schiestl C, Neuhaus K, Zoller S et al. Efficacy and safety of propranolol as first-line treatment for infantile hemangiomas. *Eur J Pediatr* 2011; 170(4): 493–501.
- Laforgia N, Milano A, De Leo E et al. Hemangioma and propranolol. Some remarks at the end of treatment. Differences from corticosteroids. *Eur J Pediatr Dermatol* 2009; 19: 175–191.

33. Manunza F, Syed S, Laquda B et al. Propranolol for complicated infantile haemangiomas: A case series of 30 infants. *Br J Dermatol* 2010; 162(2): 466–468.
34. Qin ZP, Liu XJ, Li KL et al. Treatment of infantile hemangiomas with low-dose propranolol: Evaluation of short-term efficacy and safety. *Zhonghua Yi Xue Za Zhi* 2009; 89(44): 3230–3234.
35. Sans V, de la Roque ED, Berge J et al. Propranolol for severe infantile hemangiomas: Follow-up report. *Pediatrics* 2009; 124(3): e423–e431.
36. Truong MT, Perkins JA, Messner AH et al. Propranolol for the treatment of airway hemangiomas: A case series and treatment algorithm. *Int J of Pediatr Otorhinolaryngol* 2010; 74(9): 1043–1048
37. Kim LH, Hogeling M, Wargon O et al. Propranolol: Useful therapeutic agent for the treatment of ulcerated infantile hemangiomas. *J Pediatr Surg* 2011; 46(4): 759–763.
38. Leboulangier N, Fayoux P, Teissier N et al. Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma: A preliminary retrospective study of French experience. *Int J of Pediatr Otorhinolaryngol* 2010; 74(11): 1254–1257.
39. Saint-Jean M, Léauté-Labrèze C, Mazereeuw-Hautier J et al. Propranolol for treatment of ulcerated infantile hemangiomas. *J Am Acad Dermatol* 2011; 64(5): 827–832.
40. Hermans DJ, Van Beynum IM, Schultze Kool LJ et al. Propranolol, a very promising treatment for ulceration in infantile hemangiomas: A study of 20 cases with matched historical controls. *J Am Acad Dermatol* 2011; 64(5): 833–838.
41. Maturo S, Hartnick C. Initial experience using propranolol as the sole treatment for infantile airway hemangiomas. *Int J Pediatr Otorhinolaryngol* 2010; 74(3): 323–325.
42. Haider KM, Plager DA, Neely DE et al. Outpatient treatment of periocular infantile hemangiomas with oral propranolol. *JAAPOS* 2010; 14(3): 251–256.
43. Blanchet C, Nicollas R, Bigorre M et al. Management of infantile subglottic hemangioma: Acebutolol or propranolol? *Int J Pediatr Otorhinolaryngol* 2010; 74(8): 959–961.
44. Zvulunov A, McCuaig C, Frieden IJ et al. Oral Propranolol Therapy for Infantile Hemangiomas Beyond the Proliferation Phase: A Multicenter Retrospective Study. *Pediatr Dermatol* 2011; 28(2): 94–98.
45. Peridis S, Pilgrim G, Athanasopoulos I et al. A meta-analysis on the effectiveness of propranolol for the treatment of infantile airway haemangiomas. *Int J Pediatr Otorhinolaryngol* 2011; 75(4): 455–460.
46. Buckmiller L, Dyamenahalli U, Richter GT. Propranolol for airway hemangiomas: Case report of novel treatment. *Laryngoscope* 2009; 119(10): 2051–2054.
47. Holmes WJ, Mishra A, Gorst C et al. Propranolol as first-line treatment for rapidly proliferating infantile haemangiomas. *J Plastic Reconstr Aesthet Surg* 2011; 64(4): 445–451.
48. Henry DW, Repta AJ, Smith FM et al. Stability of propranolol hydrochloride suspension compounded from tablets. *Am J Hosp Pharm* 1986; 43(6): 1492–1495.
49. Das Gupta V, Stewart KR. Stability of propranolol hydrochloride suspension and solution compounded from injection or tablets. *Am J Hosp Pharm* 1987; 44(2): 360–361.
50. Rooney M, Creurer L. Stability of propranolol hydrochloride suspension and solution. *Am J Hosp Pharm* 1988; 45(3): 530–531.
51. Brown GC, Kayes JB. The stability of suspension prepared extemporaneously from solid oral dosage forms. *J Clin Pharm* 1976; 1: 29–37.
52. Ahmed GH, Stewart PJ, Tucker IG. The stability of extemporaneous paediatric formulations of propranolol hydrochloride. *Aust J Hosp Pharm* 1988; 18(5): 312–318.
53. Modamio P, Lastra CF, Montejo O et al. Development and validation of liquid chromatography methods for the quantitation of propranolol, metoprolol, atenolol and bisoprolol: Application in solution stability studies. *Int J Pharm* 1996; 130(1): 137–140.
54. McEvoy J, ed. *AHFS Drug Information–2004*. Bethesda, MD: American Society of Health System Pharmacists; 2004.
55. Sweetman SC, ed. *MARTINDALE: The complete Drug Reference*. 33rd ed. London, UK: The Pharmaceutical Press; 2002.
56. Trissel LA. *Trissel's Stability of Compounded Formulations*. 4th ed. New York, NY: McGraw-Hill (APHA); 2009: 479.
57. Bigorre M, Van Kien AK, Valette H. Beta-blocking agent for treatment of infantile hemangioma. *Plas Reconstr Surg* 2009; 123(6): 195e–196e.
58. Singh BN, Thoden WR, Ward A. Acebutolol. A review of its pharmacological properties and therapeutic efficacy in hypertension, angina pectoris and arrhythmia. *Drugs* 1985; 29(6): 531–569.
59. Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: Insights into the molecular mechanisms of action. *Br J Dermatol* 2010; 163(2): 269–274.
60. Westfall TC, Westfall DP. Adrenergic agonists and antagonists. In: Brunton LL, Lazo JS, Parker KL, eds. *Goodman and Gilman's The Pharmacological Basis of Therapeutics*. 11th ed. New York, NY: McGraw-Hill; 2006: 271–295.
61. Westfall TC, Westfall DP. Neurotransmission: The autonomic and somatic motor nervous system. In: Brunton LL, Lazo JS, Parker KL, eds. *Goodman and Gilman's The Pharmacological Basis of Therapeutics*. 11th ed. New-York, NY: McGraw-Hill Medical Publishing Division; 2006: 167.
62. Guimarães S, Moura D. Vascular adrenoceptors: An update. *Pharmacol Rev* 2001; 53(2): 319–356.
63. Frieden IJ, Drolet BA. Propranolol for infantile hemangiomas: Promise, peril, pathogenesis. *Pediatr Dermatol* 2009; 26(5): 642–644.
64. Itinteang T, Brasch HD, Tan ST et al. Expression of components of the renin-angiotensin system in proliferating infantile haemangioma may account for the propranolol-induced accelerated involution. *J Plast Reconstr Aesthet Surg* 2011; 64(6): 759–765.
65. Bühler FR, Laragh JH, Baer L et al. Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. *N Engl J Med* 1972; 287(24): 1209–1214.
66. Ozeki M, Fukao T, Kondo N. Propranolol for intractable diffuse lymphangiomatosis. *N Engl J Med* 2011; 364(14): 1380–1382.
67. Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. *Endocr Rev* 2004; 25(4): 581–611.